Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial

European Neuropsychopharmacology

Volumn 24, Issue 6, 2014, Pages 846-855

  Hosseini, Seyed Mohammad Reza ^a   Farokhnia, Mehdi ^a   Rezaei, Farzin ^b   Gougol, Amirhossein ^a   Yekehtaz, Habibeh ^a   Iranpour, Negar ^a   Salehi, Bahman ^c   Tabrizi, Mina ^d   Tajdini, Masih ^a   Ghaleiha, Ali ^e   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DDAVP; Desmopressin; Negative symptoms; Schizophrenia; Vasopressin

Indexed keywords

DESMOPRESSIN; NOSE SPRAY; PLACEBO; RISPERIDONE; ARGIPRESSIN[1 DEAMINO]; NEUROLEPTIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DSM-IV-TR; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; HEADACHE; HUMAN; INCREASED APPETITE; MALE; MULTICENTER STUDY; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; XEROSTOMIA; ADOLESCENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DEAMINO ARGININE VASOPRESSIN; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899972170     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.02.001     Document Type: Article

References (46)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2007, 90:179-185.
2. Akhondzadeh S., Ghayyoumi R., Rezaei F., Salehi B., Modabbernia A.H., Maroufi A., Esfandiari G.R., Naderi M., Ghebleh F., Tabrizi M., Rezazadeh S.A. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berlin) 2011, 213:809-815.
3. Ang V.T., Jenkins J.S. Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog. J. Endocrinol. 1982, 93:319-325.
4. Bakermans-Kranenburg M.J., van Ijzendoorn M.H. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl. Psychiatry 2013, 3:e258.
5. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985, 10:187-191.
6. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004, 29:483-493.
7. Bielsky I.F., Hu S.B., Young L.J. Sexual dimorphism in the vasopressin system: lack of an altered behavioral phenotype in female V1a receptor knockout mice. Behav. Brain Res. 2005, 164:132-136.
8. Bohus B., de Wied D. The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin. Prog. Brain Res. 1998, 119:555-573.
9. Brambilla F., Aguglia E., Massironi R., Maggioni M., Grillo W., Castiglioni R., Catalano M., Drago F. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 1986, 15:114-121.
10. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
11. Caceda R., Kinkead B., Nemeroff C.B. Involvement of neuropeptide systems in schizophrenia: human studies. Int. Rev. Neurobiol. 2007, 78:327-376.
12. Caldwell H.K., Lee H.J., Macbeth A.H., Young W.S. Vasopressin: behavioral roles of an "original" neuropeptide. Prog. Neurobiol. 2008, 84:1-24.
13. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 2005, 76:247-265.
14. Cilia J., Gartlon J.E., Shilliam C., Dawson L.A., Moore S.H., Jones D.N. Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J. Psychopharmacol. 2010, 24:407-419.
15. De Berardis D., Marini S., Iasevoli F., Tomasetti C., de Bartolomeis A., Mazza M., Valchera A., Fornaro M., Cavuto M., Srinivasan V., Sepede G., Martinotti G., Di Giannantonio M. The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review. CNS Neurol. Disord. Drug Targets 2013, 12:252-264.
16. Engelmann M., Landgraf R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol. Behav. 1994, 55:145-149.
17. Fenton W.S., McGlashan T.H. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch. Gen. Psychiatry 1991, 48:978-986.
18. Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 2000, 1:12-14.
19. Goff D.C. Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia. World Psychiatry 2013, 12:99-107.
20. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
21. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 2009, 30:548-557.
22. Holsboer F. The role of peptides in treatment of psychiatric disorders. J Neural Transm. 2003, (Suppl.):17-34.
23. Iager A.C., Kirch D.G., Bigelow L.B., Karson C.N. Treatment of schizophrenia with a vasopressin analog. Am. J. Psychiatry 1986, 143:375-377.
24. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
25. Khodaie-Ardakani M.R., Seddighi S., Modabbernia A., Rezaei F., Salehi B., Ashrafi M., Shams-Alizadeh N., Mohammad-Karimi M., Esfandiari G.R., Hajiaghaee R., Akhondzadeh S. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J. Psychiatr. Res. 2013, 47:472-478.
26. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
27. Korsgaard S., Casey D.E., Damgaard Pedersen N.E., Jorgensen A., Gerlach J. Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo. Psychopharmacology (Berlin) 1981, 74:379-382.
28. Lacrosse A.L., Olive M.F. Neuropeptide systems and schizophrenia. CNS Neurol. Disord. Drug Targets 2013, 12:619-632.
29. Laycock J.F., Gartside I.B., Chapman J.T. A comparison of the learning abilities of Brattleboro rats with hereditary diabetes insipidus and Long-Evans rats using positively reinforced operant conditioning. Prog. Brain Res. 1983, 60:183-187.
30. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012, 64:614-628.
31. Macdonald K., Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012, 24:130-146.
32. Matsuoka T., Sumiyoshi T., Tanaka K., Tsunoda M., Uehara T., Itoh H., Kurachi M. NC-1900, an arginine-vasopressin analog, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia. Brain Res. 2005, 1053:131-136.
33. McCall C., Singer T. The animal and human neuroendocrinology of social cognition, motivation and behavior. Nat. Neurosci. 2012, 15:681-688.
34. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., Hosseini S.M., Tajdini M., Ghaleiha A., Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27:57-65.
35. Murphy B.P., Chung Y.C., Park T.W., McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr. Res. 2006, 88:5-25.
36. Noroozian M., Ghasemi S., Hosseini S.M., Modabbernia A., Khodaie-Ardakani M.R., Mirshafiee O., Farokhnia M., Tajdini M., Rezaei F., Salehi B., Ashrafi M., Yekehtaz H., Tabrizi M., Akhondzadeh S. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berlin) 2013, 228:595-602.
37. Raskind M.A., Peskind E.R., Lampe T.H., Risse S.C., Taborsky G.J., Dorsa D. Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer[U+05F3]s disease. Arch. Gen. Psychiatry 1986, 43:382-388.
38. Rezaei F., Mohammad-Karimi M., Seddighi S., Modabbernia A., Ashrafi M., Salehi B., Hammidi S., Motasami H., Hajiaghaee R., Tabrizi M., Akhondzadeh S. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2013, 33:336-342.
39. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 1995, 6:55-65.
40. Sorensen P.S., Gjerris A., Hammer M. Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J. Neurol. Neurosurg. Psychiatry 1985, 48:50-57.
41. Tanaka K., Suzuki M., Sumiyoshi T., Murata M., Tsunoda M., Kurachi M. Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Brain Res. 2003, 992:239-245.
42. Vande Walle J., Stockner M., Raes A., Norgaard J.P. Desmopressin 30 years in clinical use: a safety review. Curr. Drug Saf. 2007, 2:232-238.
43. de Wied D., van Ree J.M. Neuropeptides: animal behaviour and human psychopathology. Eur. Arch. Psychiatry Neurol. Sci. 1989, 238:323-331.
44. Williams A.R., Carey R.J., Miller M. Behavioral differences between vasopressin-deficient (Brattleboro) and normal Long-Evans rats. Peptides 1983, 4:711-716.
45. Winslow J.T., Insel T.R. Neuroendocrine basis of social recognition. Curr. Opin. Neurobiol. 2004, 14:248-253.
46. Zhu J., Jiang Y., Xu G., Liu X. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors. Histol. Histopathol. 2012, 27:537-548.